The estimated Net Worth of James William Burns is at least $1.87 Milion dollars as of 1 March 2024. James Burns owns over 7,834 units of Agios Pharmaceuticals Inc stock worth over $1,706,733 and over the last 3 years James sold AGIO stock worth over $168,061.
James has made over 13 trades of the Agios Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently James exercised 7,834 units of AGIO stock worth $347,125 on 1 March 2024.
The largest trade James's ever made was exercising 8,750 units of Agios Pharmaceuticals Inc stock on 23 December 2022 worth over $387,713. On average, James trades about 4,037 units every 54 days since 2022. As of 1 March 2024 James still owns at least 38,518 units of Agios Pharmaceuticals Inc stock.
You can see the complete history of James Burns stock trades at the bottom of the page.
Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over $77,887,085 worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth $154,554,190 . The most active insiders traders include Kevin P Starr, Robert Nelsen a John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $765,588. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth $102,002.
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include: